DRMA vs. PASG, VYNE, LEXX, CMMB, ALVR, ALLR, TXMD, BFRG, GLYC, and PMN
Should you be buying Dermata Therapeutics stock or one of its competitors? The main competitors of Dermata Therapeutics include Passage Bio (PASG), VYNE Therapeutics (VYNE), Lexaria Bioscience (LEXX), Chemomab Therapeutics (CMMB), AlloVir (ALVR), Allarity Therapeutics (ALLR), TherapeuticsMD (TXMD), Bullfrog AI (BFRG), GlycoMimetics (GLYC), and ProMIS Neurosciences (PMN). These companies are all part of the "pharmaceutical products" industry.
Dermata Therapeutics vs.
Passage Bio (NASDAQ:PASG) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, community ranking, institutional ownership, dividends, risk, profitability, media sentiment and valuation.
Passage Bio has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500. Comparatively, Dermata Therapeutics has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.
Passage Bio's return on equity of -72.53% beat Dermata Therapeutics' return on equity.
In the previous week, Passage Bio had 4 more articles in the media than Dermata Therapeutics. MarketBeat recorded 5 mentions for Passage Bio and 1 mentions for Dermata Therapeutics. Dermata Therapeutics' average media sentiment score of 0.00 beat Passage Bio's score of -0.59 indicating that Dermata Therapeutics is being referred to more favorably in the news media.
Passage Bio is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.
Passage Bio received 47 more outperform votes than Dermata Therapeutics when rated by MarketBeat users. Likewise, 68.83% of users gave Passage Bio an outperform vote while only 54.55% of users gave Dermata Therapeutics an outperform vote.
53.5% of Passage Bio shares are held by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are held by institutional investors. 5.0% of Passage Bio shares are held by insiders. Comparatively, 9.4% of Dermata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Passage Bio presently has a consensus price target of $7.50, suggesting a potential upside of 2,391.69%. Dermata Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 289.51%. Given Passage Bio's higher possible upside, equities analysts plainly believe Passage Bio is more favorable than Dermata Therapeutics.
Summary
Passage Bio beats Dermata Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Dermata Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dermata Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:DRMA) was last updated on 5/21/2025 by MarketBeat.com Staff
Buy DRMA Stock Free DRMA Stock Alerts